Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 496

1.

Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials.

Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassaï B, Erpeldinger S, Wright JM, Gueyffier F, Cornu C.

BMJ. 2011 Jul 26;343:d4169. doi: 10.1136/bmj.d4169. Review.

2.

Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials.

Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal T, Hemmingsen C, Wetterslev J.

BMJ. 2011 Nov 24;343:d6898. doi: 10.1136/bmj.d6898. Review.

3.

Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.

Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal T, Hemmingsen C, Wetterslev J.

Cochrane Database Syst Rev. 2011 Jun 15;(6):CD008143. doi: 10.1002/14651858.CD008143.pub2. Review. Update in: Cochrane Database Syst Rev. 2013;11:CD008143.

PMID:
21678374
4.

Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.

Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal TP, Hemmingsen C, Wetterslev J.

Cochrane Database Syst Rev. 2013 Nov 11;11:CD008143. doi: 10.1002/14651858.CD008143.pub3. Review. Update in: Cochrane Database Syst Rev. 2015;7:CD008143.

PMID:
24214280
5.

The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study.

Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA, Dudl RJ, Ismail-Beigi F, Kimel AR, Hoogwerf B, Horowitz KR, Savage PJ, Seaquist ER, Simmons DL, Sivitz WI, Speril-Hillen JM, Sweeney ME.

BMJ. 2010 Jan 8;340:b4909. doi: 10.1136/bmj.b4909.

6.

Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials.

Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, Erqou S, Sattar N.

Lancet. 2009 May 23;373(9677):1765-72. doi: 10.1016/S0140-6736(09)60697-8.

PMID:
19465231
7.

Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.

Tandon N, Ali MK, Narayan KM.

Am J Cardiovasc Drugs. 2012 Feb 1;12(1):7-22. doi: 10.2165/11594650-000000000-00000. Review.

PMID:
22217193
8.

Effect of Intensive Versus Standard Blood Glucose Control in Patients With Type 2 Diabetes Mellitus in Different Regions of the World: Systematic Review and Meta-analysis of Randomized Controlled Trials.

Sardar P, Udell JA, Chatterjee S, Bansilal S, Mukherjee D, Farkouh ME.

J Am Heart Assoc. 2015 May 5;4(5). pii: e001577. doi: 10.1161/JAHA.114.001577. Review.

9.

Intensive glucose control and cardiovascular outcomes in type 2 diabetes.

Macisaac RJ, Jerums G.

Heart Lung Circ. 2011 Oct;20(10):647-54. doi: 10.1016/j.hlc.2010.07.013. Epub 2010 Aug 31. Review.

PMID:
20807681
10.

Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial.

Zoungas S, de Galan BE, Ninomiya T, Grobbee D, Hamet P, Heller S, MacMahon S, Marre M, Neal B, Patel A, Woodward M, Chalmers J; ADVANCE Collaborative Group, Cass A, Glasziou P, Harrap S, Lisheng L, Mancia G, Pillai A, Poulter N, Perkovic V, Travert F.

Diabetes Care. 2009 Nov;32(11):2068-74. doi: 10.2337/dc09-0959. Epub 2009 Aug 3.

11.

Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials.

Boussageon R, Supper I, Bejan-Angoulvant T, Kellou N, Cucherat M, Boissel JP, Kassai B, Moreau A, Gueyffier F, Cornu C.

PLoS Med. 2012;9(4):e1001204. doi: 10.1371/journal.pmed.1001204. Epub 2012 Apr 10.

12.

The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus.

Huang ES, Meigs JB, Singer DE.

Am J Med. 2001 Dec 1;111(8):633-42.

PMID:
11755507
13.

Influence of intensive versus conventional glucose control on microvascular and macrovascular complications in type 1 and 2 diabetes mellitus.

Mattila TK, de Boer A.

Drugs. 2010 Dec 3;70(17):2229-45. doi: 10.2165/11585220-000000000-00000. Review.

PMID:
21080740
14.

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F.

N Engl J Med. 2008 Jun 12;358(24):2560-72. doi: 10.1056/NEJMoa0802987. Epub 2008 Jun 6.

16.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
18.

Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials.

Costa J, Borges M, David C, Vaz Carneiro A.

BMJ. 2006 May 13;332(7550):1115-24. Epub 2006 Apr 3. Review.

19.

Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials.

Mannucci E, Monami M, Lamanna C, Gori F, Marchionni N.

Nutr Metab Cardiovasc Dis. 2009 Nov;19(9):604-12. doi: 10.1016/j.numecd.2009.03.021. Epub 2009 May 8.

PMID:
19427768
20.

Perioperative glycaemic control for diabetic patients undergoing surgery.

Buchleitner AM, Martínez-Alonso M, Hernández M, Solà I, Mauricio D.

Cochrane Database Syst Rev. 2012 Sep 12;9:CD007315. doi: 10.1002/14651858.CD007315.pub2. Review.

PMID:
22972106
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk